argenex (ARGX) Stock Price, News & Analysis

Company Overview

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders. Efgartigimod has advanced through pivotal clinical trials and has received regulatory approvals in major markets for indications that include generalized myasthenia gravis, with additional development underway in other immune-mediated conditions. Argenx maintains a broader pipeline of antibody candidates exploring complementary mechanisms and additional indications within autoimmune and neuromuscular disease areas.

argenx operates across major life sciences markets, carrying out clinical development and commercialization activities in Europe and the United States and engaging with global regulatory authorities as it expands label and market access for its therapies. The company has evolved from a discovery-stage biotech into a commercial-stage organization as it scales manufacturing, regulatory and commercial functions to support patient access and ongoing clinical programs.

For investors and industry observers, argenx is notable for its platform-driven approach to antibody engineering, its focus on FcRn biology as a therapeutic mechanism, and its transition toward commercial operations following regulatory milestones for its lead therapy. The company continues to advance clinical studies and seek approvals in additional indications while expanding commercial infrastructure to support its marketed products and pipeline candidates.

Key Stats

• Today's Range: $829.60 to $841.85
• 50-Day Range: $663.93 to $849.04
• 52-Week Range: $510.05 to $934.62
• Volume: 192,485 shs
• Average Volume: 304,605 shs
• Market Capitalization: $51.99 billion
• P/E Ratio: 37.22
• Dividend Yield: N/A
• Price Target: $1,017.78
• Consensus Rating: Moderate Buy

argenex Stock Analysis - MarketRank™

argenex scored higher than 80% of companies evaluated by MarketBeat, and ranked 145th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

argenex has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 2 strong buy ratings, 18 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

argenex has a consensus price target of $1,017.78, representing about 21.7% upside from its current price of $835.99.

Amount of Analyst Coverage

argenex has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 28.77%

Earnings Growth

Earnings for argenex are expected to grow by 28.77% in the coming year, from $25.27 to $32.54 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of argenex is 37.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.88.

Price to Earnings Ratio vs. Sector

The P/E ratio of argenex is 37.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.20.

Price to Earnings Growth Ratio

argenex has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

argenex has a P/B Ratio of 7.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.56% of the float of argenex has been sold short.

Short Interest Ratio / Days to Cover

argenex has a short interest ratio ("days to cover") of 6.22.

Change versus previous month

Short interest in argenex has recently increased by 3.52%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

argenex does not currently pay a dividend.

Dividend Growth

argenex does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.38

News Sentiment

argenex has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for argenex this week, compared to 7 articles on an average week.

Search Interest

23 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.

MarketBeat Follows

6 people have added argenex to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, argenex insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.43% of the stock of argenex is held by insiders.

Percentage Held by Institutions

60.32% of the stock of argenex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 5/30/2026
• 46th Annual William Blair Growth Stock Conference: 6/03/2026
• Goldman Sachs 47th Annual Global Healthcare Conference 2026: 6/09/2026
• Status update: 6/23/2026
• Next Earnings (Estimated): 7/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARGX
• Previous Symbol: NASDAQ:ARGX
• CIK: 1697862
• Web: www.argenx.com
• Phone: (176) 303-0488
• Fax: N/A
• Employees: 1,863
• Year Founded: 2008

Price Target and Rating

• Average Price Target for argenex: $1,017.78
• High Price Target: $1,260.00
• Low Price Target: $818.00
• Potential Upside/Downside: +21.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $22.46
• Trailing P/E Ratio: 37.22
• Forward P/E Ratio: 33.08
• P/E Growth: 1.33
• Net Income: $1.29 billion
• Net Margins: 31.31%
• Pretax Margin: 30.10%
• Return on Equity: 33.28%
• Return on Assets: 28.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.23
• Quick Ratio: 4.87

Sales & Book Value

• Annual Sales: $4.66 billion
• Price / Sales: 11.15
• Cash Flow: $21.27 per share
• Price / Cash Flow: 39.31
• Book Value: $118.34 per share
• Price / Book: 7.06

Miscellaneous

• Outstanding Shares: 62,188,000
• Free Float: 60,677,000
• Market Cap: $51.99 billion
• Optionable: Optionable
• Beta: 0.46